CMN Weekly (8 November 2024) - Your Weekly CRISPR...
CMN Weekly
Nov. 8, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Caszyme
Company Type: Provider of CRISPR-based molecular tools
Main focus: Developing and characterising new tools in support of CRISPR-Cas gene editing technology research
Company stage: Startup
Diseases: N/A
Genome-editing tool: CRISPR
Funding stage: Unknown
Location: Vilnius, Lithuania
Website: https://caszyme.com/
Pipeline: N/A
Partners: https://caszyme.com/partners
Caszyme is a startup company founded in 2017. Based in Vilnius, Lithuania, the company aims to develop new discoveries, innovative applications and top-quality research in the field of CRISPR-based molecular tools. Caszyme was founded by scientists which were first to demonstrate that CRISPR-Cas9 can be used to operate precise double-stranded breaks in DNA, thereby enabling a new era of gene editing. The founders have outstanding expertise within Cas9 and other CRISPR-Cas protein expression, purification and characterisation, as well as bioinformatic analysis of the CRISPR-Cas system.
